Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Launched by PETTER BJORNSTAD · Aug 9, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The PANTHER Study is a clinical trial aimed at understanding how puberty affects kidney health in young people with type 2 diabetes (T2D) and obesity. Research shows that many adolescents with T2D develop early signs of kidney disease, which can lead to serious health issues later in life. This study seeks to explore the connection between the changes that occur during puberty and the onset of diabetes in young people, hoping to find ways to protect kidney function during this critical time.
To participate in the trial, young individuals aged between 13 and 21 years who either have high blood sugar levels (HbA1c of 6.0% or higher) and are overweight, or those who are healthy with normal blood sugar levels (HbA1c of 5.6% or lower) may be eligible. However, those with a history of kidney problems or certain health conditions, like allergies to specific medications or pregnancy, cannot join. Participants can expect to undergo various assessments to better understand their health and how puberty may impact their kidneys. This research is important as it aims to improve the long-term health of young people living with diabetes and obesity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HbA1c ≥6.0% for untreated high-risk group
- • BMI ≥ 85th %ile for high-risk group
- • Normal HbA1c ≤5.6% for control group
- • Type 1 diabetes (T1D) Antibody negative
- Exclusion Criteria:
- • History of Chronic kidney disease (CKD) or acute kidney injury (AKI)
- • Metabolic disorder prohibiting safe fasting
- • Iodine or penicillin allergy
- • Pregnancy
- • Thrombophilia
- • MRI contraindications
- • Hormone therapy
About Petter Bjornstad
Petter Bjornstad is a dedicated clinical trial sponsor specializing in the development and management of innovative research initiatives aimed at advancing medical science and improving patient outcomes. With a strong focus on ethical practices and regulatory compliance, Mr. Bjornstad leads a team of experienced professionals committed to conducting high-quality clinical trials across various therapeutic areas. His expertise in trial design and execution, combined with a deep understanding of the regulatory landscape, ensures that each study is meticulously planned and carried out, fostering collaboration with healthcare providers and research institutions to drive meaningful advancements in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Seattle, Washington, United States
Patients applied
Trial Officials
Petter Bjornstad, MD
Principal Investigator
University of Washington - Medicine Diabetes Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials